OrbiMed Advisors Acquires Additional Shares of RAPT Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 15 2026
0mins
Source: Fool
- Share Acquisition: On February 17, 2026, OrbiMed Advisors purchased an additional 556,273 shares of RAPT Therapeutics, with an estimated transaction value of $17.28 million based on the average closing price for Q4 2025, indicating strong confidence in the company's growth prospects.
- Holding Overview: Following this acquisition, OrbiMed's total holdings in RAPT reached 1,642,891 shares valued at $55.64 million, representing 1.1% of its 13F reportable AUM, highlighting its strategic positioning in the biotech sector.
- Market Reaction: RAPT announced on February 2, 2026, that it would be acquired by GSK for $58 per share, approximately 75% above its stock price of $33.15 on December 31, 2025, reflecting the high valuation large pharmaceutical companies place on promising immunology assets.
- Investment Outlook: RAPT focuses on developing oral small-molecule therapies for oncology and inflammatory diseases, with its anti-IgE antibody candidate ozureprubart aimed at preventing severe allergic reactions, addressing a significant health challenge faced by over 17 million people in the U.S., showcasing its market potential.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
